Research Article
Micronization of insulin from halogenated alcohol solution using supercritical carbon dioxide as an antisolvent
Article first published online: 14 JUN 2002
DOI: 10.1002/jps.10193
Copyright © 2002 Wiley-Liss, Inc.
Total views since August 2010: 160
Additional Information
How to Cite
Snavely, W. K., Subramaniam, B., Rajewski, R. A. and Defelippis, M. R. (2002), Micronization of insulin from halogenated alcohol solution using supercritical carbon dioxide as an antisolvent. J. Pharm. Sci., 91: 2026–2039. doi: 10.1002/jps.10193
Publication History
- Issue published online: 14 JUN 2002
- Article first published online: 14 JUN 2002
- Manuscript Accepted: 21 MAR 2002
- Manuscript Revised: 9 MAR 2002
- Manuscript Received: 20 NOV 2001
Keywords:
- insulin;
- supercritical carbon dioxide;
- micronization;
- particles
Abstract
Insulin was precipitated from solution in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) using supercritical carbon dioxide (CO2) as an antisolvent. Biosynthetic human insulin crystals were dissolved in HFIP and the solution was sprayed through an ultrasonic nozzle into supercritical CO2. The factors in the 23 factorial experimental design with a center point replicate included pressure (83.7 and 97.5 bar), solution concentration (15 and 30 mg/mL), and solution flow rate (2 and 4 mL/min). Temperature (37°C), CO2 mass flow rate (137 g/min), and volume of solution sprayed (20 mL) were held constant. High-performance liquid chromatography, circular dichroism spectroscopy, infrared and Raman spectroscopy, scanning electron microscopy, dry powder size distribution analysis, thermogravimetric analysis, and atomic absorption spectroscopy were used to characterize the processed insulin powder. The processed insulin retained its potency, was slightly degraded chemically, and exhibited reversible structural changes. The precipitated powder consisted of physical aggregates of 50-nm spheres. Through deagglomeration of these aggregates, it may be possible to obtain discrete uniform particles (1–5 μm) suitable for pulmonary therapy. Over the ranges of operating variables studied, the factors chosen for the experimental design had little effect on the product characteristics. © 2002 Wiley-Liss Inc. and the American Pharmaceutical Association J Pharm Sci 91:2026–2039, 2002

1520-6017/asset/JPS_left.gif?v=1&s=becd26fac43b87042ad04af68bbe20d6a12e64fc)
1520-6017/asset/olbannerright.jpg?v=1&s=254f44b422de0f476861bd1056a1789033e2171c)
1520-6017/asset/cover.gif?v=1&s=e589ccf35fd012c675e943835781318cb8666bed)